MCP
PACB icon

Mirador Capital Partners’s Pacific Biosciences PACB Stock Holding History

Mirador Capital Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$575K Sell
342,482
-262,402
-43% -$382K 0.07% 145
2026
Q1 		$798K Buy
604,884
+13,879
+2% +$24.8K 0.11% 109
2025
Q4 		$1.11M Buy
591,005
+9,612
+2% +$18.5K 0.15% 95
2025
Q3 		$744K Buy
581,393
+17,723
+3% +$24K 0.11% 122
2025
Q2 		$699K Buy
563,670
+47,936
+9% +$55.4K 0.11% 116
2025
Q1 		$609K Buy
515,734
+289,148
+128% +$444K 0.11% 119
2024
Q4 		$415K Buy
226,586
+3,374
+2% +$6.59K 0.08% 140
2024
Q3 		$379K Buy
223,212
+161,818
+264% +$266K 0.07% 148
2024
Q2 		$84.1K Sell
61,394
-256,979
-81% -$519K 0.02% 185
2024
Q1 		$1.19M Buy
318,373
+265,835
+506% +$1.56M 0.23% 72
2023
Q4 		$515K Buy
52,538
+26,951
+105% +$220K 0.11% 114
2023
Q3 		$214K Buy
25,587
+14,112
+123% +$161K 0.05% 174
2023
Q2 		$153K Sell
11,475
-1,500
-12% -$18.2K 0.04% 180
2023
Q1 		$150K Sell
12,975
-3,058
-19% -$30.4K 0.04% 184
2022
Q4 		$131K Buy
+16,033
New +$138K 0.03% 186

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mirador Capital Partners's PACB Position: Q2 2026 in Review

Mirador Capital Partners reduced its Pacific Biosciences (PACB) stake by 43% in Q2 2026, selling an estimated $382K and leaving 342,482 shares worth $575K. The position accounts for 0.07% of the portfolio, ranked #145.

Mirador Capital Partners first reported a position in PACB in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.19M in Q1 2024. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Mirador Capital Partners held 342,482 shares of Pacific Biosciences worth $575K as of Q2 2026.
  • Mirador Capital Partners sold 262,402 Pacific Biosciences shares in Q2 2026, an estimated $382K.
  • Pacific Biosciences made up 0.07% of Mirador Capital Partners's portfolio in Q2 2026, its #145 holding.
  • Mirador Capital Partners first reported a position in Pacific Biosciences in Q4 2022 and has held it in 15 quarters since.
  • Mirador Capital Partners's Pacific Biosciences position peaked at $1.19M in Q1 2024.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Mirador Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.